Work

A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.5072

Authors: Fatima Karzai, Avani Atul Shah, Michelle A. Ojemuyiwa, Ravi Amrit Madan, Andrea Borghese Apolo, Nancy Ann Dawson, Philip M. Arlen, Marc Robert Theoret, John Joseph Wright, Clara Chen, Jane B. Trepel, Anna Couvillon, Guinevere Chun, Nancy Harold, Seth M. Steinberg, Douglas K. Price, James L. Gulley, William Douglas Figg, William L. Dahut

Institutions: National Institutes of Health, National Cancer Institute, Walter Reed National Military Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, National Institutes of Health Clinical Center, Center for Cancer Research

Language: French

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4234056003

Cites:

Cited by:

Related to: 10